These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27128181)

  • 1. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.
    Esvan YJ; Zeinyeh W; Boibessot T; Nauton L; Théry V; Knapp S; Chaikuad A; Loaëc N; Meijer L; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2016 Aug; 118():170-7. PubMed ID: 27128181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives.
    Zeinyeh W; Esvan YJ; Nauton L; Loaëc N; Meijer L; Théry V; Anizon F; Giraud F; Moreau P
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4327-9. PubMed ID: 27469128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.
    Zeinyeh W; Esvan YJ; Josselin B; Baratte B; Bach S; Nauton L; Théry V; Ruchaud S; Anizon F; Giraud F; Moreau P
    Bioorg Med Chem; 2019 May; 27(10):2083-2089. PubMed ID: 30967303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I.
    Foucourt A; Hédou D; Dubouilh-Benard C; Désiré L; Casagrande AS; Leblond B; Loäec N; Meijer L; Besson T
    Molecules; 2014 Sep; 19(10):15546-71. PubMed ID: 25268714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.
    Foucourt A; Hédou D; Dubouilh-Benard C; Girard A; Taverne T; Casagrande AS; Désiré L; Leblond B; Besson T
    Molecules; 2014 Sep; 19(10):15411-39. PubMed ID: 25264830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
    Liu KK; Huang X; Bagrodia S; Chen JH; Greasley S; Cheng H; Sun S; Knighton D; Rodgers C; Rafidi K; Zou A; Xiao J; Yan S
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1270-4. PubMed ID: 21269826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.
    Waiker DK; Karthikeyan C; Poongavanam V; Kongsted J; Lozach O; Meijer L; Trivedi P
    Bioorg Med Chem; 2014 Mar; 22(6):1909-15. PubMed ID: 24530227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
    Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
    Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
    Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors.
    Gellibert F; Fouchet MH; Nguyen VL; Wang R; Krysa G; de Gouville AC; Huet S; Dodic N
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2277-81. PubMed ID: 19285388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors.
    Loidreau Y; Deau E; Marchand P; Nourrisson MR; Logé C; Coadou G; Loaëc N; Meijer L; Besson T
    Eur J Med Chem; 2015 Mar; 92():124-34. PubMed ID: 25549552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of quinazolines as tyrosine kinase inhibitors.
    Srivastava SK; Kumar V; Agarwal SK; Mukherjee R; Burman AC
    Anticancer Agents Med Chem; 2009 Mar; 9(3):246-75. PubMed ID: 19275520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors.
    Loidreau Y; Marchand P; Dubouilh-Benard C; Nourrisson MR; Duflos M; Lozach O; Loaëc N; Meijer L; Besson T
    Eur J Med Chem; 2012 Dec; 58():171-83. PubMed ID: 23124214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Kinase Inhibitors via Metal-Catalyzed C⁻H Arylation of 8-Alkyl-thiazolo[5,4-
    Couly F; Harari M; Dubouilh-Benard C; Bailly L; Petit E; Diharce J; Bonnet P; Meijer L; Fruit C; Besson T
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30158487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases.
    Deau E; Loidreau Y; Marchand P; Nourrisson MR; Loaëc N; Meijer L; Levacher V; Besson T
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6784-8. PubMed ID: 24176400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.
    Heron NM; Anderson M; Blowers DP; Breed J; Eden JM; Green S; Hill GB; Johnson T; Jung FH; McMiken HH; Mortlock AA; Pannifer AD; Pauptit RA; Pink J; Roberts NJ; Rowsell S
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1320-3. PubMed ID: 16337122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
    Mariano M; Hartmann RW; Engel M
    Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.
    Converso A; Hartingh T; Garbaccio RM; Tasber E; Rickert K; Fraley ME; Yan Y; Kreatsoulas C; Stirdivant S; Drakas B; Walsh ES; Hamilton K; Buser CA; Mao X; Abrams MT; Beck SC; Tao W; Lobell R; Sepp-Lorenzino L; Zugay-Murphy J; Sardana V; Munshi SK; Jezequel-Sur SM; Zuck PD; Hartman GD
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1240-4. PubMed ID: 19155174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.